On September 29, 2026, a clinical trial record update was logged for a study involving triptorelin. The trial, titled "Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer," is registered as NCT01492972. It is listed as a Phase 3 study. Its current status is recruiting, meaning the trial is actively enrolling participants as of this update.
The study is evaluating hypo-fractionated radiation therapy given with or without androgen suppression in patients with intermediate risk prostate cancer. Triptorelin is an approved compound and is used in this context as part of an androgen suppression approach being studied alongside radiation therapy. No outcome data, interim results, or efficacy findings have been reported in this update. The listing reflects only the trial's design, phase, and recruitment status as of the date given.
Readers interested in the underlying therapy can consult the compound overview for background on triptorelin and its approved regulatory status.